AboutContact us
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Intel expansion uncertainty grows as Israel does not transfer $425 million grant
2
China just dropped a 2.8-trillion-parameter bomb on the AI race
3
Intel’s revival begins with a problem most companies want
4
Israeli AI robotics startup Enigma emerges from stealth with $71 million Seed round
5
Wiz’s AI hacker hunter: “I used to hope I found a vulnerability overnight. Today AI tells me it hacked the organization”
More news

BioProtect

4 stories about BioProtect
מנכ"ל ביופרוטקט איתי ברנע ו משרדי אולימפוס ב הולנד

Olympus to buy Israel’s BioProtect for $270 million in cash

26.05.26|Meir Orbach
Japanese medtech group expands into prostate cancer treatment devices with all-cash deal. 
Itay Barnea BioProtect

Is it time to reconsider PSA tests for Prostate Cancer?

01.09.22|Itay Barnea
“The treating physician should determine what is best for the patient based on his unique age, family history, health, lifestyle, race, ethnic background, and other factors,” writes Itay Barnea, CEO of BioProtect
חולה קורונה אשפוז בית חולים רופאים ג'נבה ז'נווה שוויץ

Which Israeli cancer treatment company raised $57 million and who is making money off double chins?

22.09.20|CTech
CTech Daily Roundup: Medtronic invests $4.5 million as part of BioProtect $25 million series D
מוסף ניתוח מנתח מנתחים רופא רופאים

Medtronic invests $4.5 million as part of BioProtect $25 million series D

22.09.20|Meir Orbach
Proceeds of the round will finance the ongoing multicenter FDA clinical trial of BioProtect's lead product, the ProSpace balloon spacer, which protects prostate cancer patients undergoing radiation therapy